Analyst Vernon Bernardino of H.C. Wainwright reiterated a Buy rating on Dyadic International (DYAI – Research Report), with a price target of $6.00.
Vernon Bernardino has given his Buy rating due to several factors that reflect positively on Dyadic International’s growth prospects. One of the primary reasons is Dyadic International’s recent collaboration with the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital. This collaboration will use Dyadic’s proprietary C1 protein production platform to develop vaccine antigens for influenza A and other infectious diseases. This partnership, supported by a substantial $5.88M award from the U.S. Department of Defense, promises a significant commercial opportunity for Dyadic.
The C1 platform is Dyadic’s leading technology. It is a unique cell protein production platform that can potentially enhance the development process and reduce the production cost of vaccines and biologic drugs. The technology has shown potential to allow cost-efficient production of large quantities of antigens and vaccines in a relatively short time. Furthermore, Dyadic’s potential to announce more collaborations in the forthcoming months could serve as positive catalysts for the stock. Bernardino therefore confirms the Buy rating and $6 price target, despite acknowledging certain risks such as clinical trial failures, additional regulatory requirements, and potential poor market conditions.
Bernardino covers the Healthcare sector, focusing on stocks such as Cassava Sciences, Citius Pharmaceuticals, and Candel Therapeutics. According to TipRanks, Bernardino has an average return of 5.1% and a 25.20% success rate on recommended stocks.
See today’s best-performing stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Dyadic International (DYAI) Company Description:
Dyadic International, Inc. engages in developing a gene expression platform for producing commercial quantities of industrial enzymes and other proteins. It focuses on further improving and applying its proprietary C1 technology, which is used in the discovery, development, and manufacture of biologic medicines and vaccines. The company was founded by Mark A. Emalfarb in 1979 and is headquartered in Jupiter, FL.
Read More on DYAI:
- Dyadic Appoints Doug Pace to Its Executive Leadership Team
- Dyadic International appoints Doug Pace as EVP, business development
- Dyadic enters research collaboration with VIC at Massachusetts General Hospital
- Dyadic’s C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC’s $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic Vaccines for Infectious Diseases
- Dyadic to Present at Industry and Investor Events in October
